Opportunities to encourage adoption of a biomarker-enabled care pathway for Alzheimer's in primary care.

ABSTRACT: Identification of early-stage Alzheimer's disease (AD) remains a challenge due to limited specialist availability, diagnostic access, disease awareness, and cultural factors. Blood-based biomarkers (BBBM) could play a critical role in the identification and referral of patients suspected of AD to specialty care. A multidisciplinary AD Biomarker Task Force was convened to evaluate current biomarker use cases, define an optimal biomarker-enabled AD diagnostic care pathway, and understand factors impacting adoption. The Task Force identified opportunities to support biomarker-enabled AD diagnostic care pathway adoption, including streamlining risk assessment and screening by leveraging digital tools, activating primary care providers through education, generating data to expand applicability

SUBMITTER: Borson S 

PROVIDER: S-EPMC11895972 | biostudies-literature | 2025 Jan-Mar

REPOSITORIES: biostudies-literature